EVER(Epidermodysplasia Verruciformis Levandowsky-Lutz)/TMC(TransMembral Channel Like Protein) Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients

This study is currently recruiting participants.
Verified September 2013 by University Hospital, Basel, Switzerland
Sponsor:
Information provided by (Responsible Party):
Andreas Arnold, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT01942005
First received: August 7, 2013
Last updated: September 9, 2013
Last verified: September 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)